Abstract: The disclosure relates to a tofacitinib citrate sustained-release tablet and a preparation method thereof. The tofacitinib citrate sustained-release tablet includes the components in parts by weight: 35.54 parts of tofacitinib citrate, 90-130 parts of diluent, 20-40 parts of binder, 20-40 parts of matrix material, 0.5-1.5 parts of glidant, 1-3 parts of lubricant, and 25.5-53 parts of sustained-release coating material. The sustained-release coating is a mixture of hypromellose, plasticizer and mineral hydrophobic material. The plasticizer is polyethylene glycol. The mineral hydrophobic material is any one of kaolin, talc powder, and heavy density calcium carbonate.